"Follow-On" Biologics Framework Development Will Become More Public Process, FDA's Kweder Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency is still struggling with scientific issues, the Office of New Drugs deputy director says. A delay in the public comment process should not be perceived as FDA "just being secretive."